Mirabegron Zentiva (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors on the bladder’s detrusor muscle. This activation raises cyclic AMP levels, causing the muscle to relax during the filling phase, which expands bladder capacity and reduces involuntary contractions that trigger urgency.

The dosage of Mirabegron Zentiva is individualized by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Antimuscarinic drugs such as oxybutynin reduce bladder contractions by blocking muscarinic receptors, often causing dry mouth and constipation. Mirabegron, a β3‑agonist, relaxes the detrusor muscle via a different pathway and typically has a lower incidence of anticholinergic side effects, offering an alternative for patients who cannot tolerate antimuscarinics.

Mirabegron Zentiva should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

The medication is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include significant hypertension, acute urinary retention, and QT‑interval prolongation, which can predispose to cardiac arrhythmias. Patients should be monitored for elevated blood pressure and any signs of urinary obstruction, and an ECG may be considered in those with cardiac risk factors.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any excipients. Caution is also advised for individuals taking strong CYP2D6 inhibitors or drugs that prolong the QT interval.